Diabetes and COVID-19

Several factors are linked with a higher risk of mortality from Coronavirus disease-19 (COVID-19), including male gender, increased age, hypertension, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, and cancer. Hyperglycemic COVID-19 patients have severe c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Gazzaz Zohair Jamil
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2021
Materias:	diabetes mellitus covid-19 ace2 cytokine storm cvd Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/a2e578d5f8454730bff6e533b8358c46
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a2e578d5f8454730bff6e533b8358c46
record_format	dspace
spelling	oai:doaj.org-article:a2e578d5f8454730bff6e533b8358c462021-12-05T14:10:41ZDiabetes and COVID-192391-541210.1515/biol-2021-0034https://doaj.org/article/a2e578d5f8454730bff6e533b8358c462021-03-01T00:00:00Zhttps://doi.org/10.1515/biol-2021-0034https://doaj.org/toc/2391-5412Several factors are linked with a higher risk of mortality from Coronavirus disease-19 (COVID-19), including male gender, increased age, hypertension, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, and cancer. Hyperglycemic COVID-19 patients have severe clinical problems, increased ICU admittance, machine-driven ventilation, and a substantial rise in inflammatory markers. Among all patients, those with diabetes or hyperglycemia have a two- to four-fold increase in mortality and severity of COVID-19 than those without diabetes. The primary cause of mortality in COVID-19 patients with diabetes is compromised immune response to viral infections. Increased blood sugar level probably affects intracellular degradation of bacteria, neutrophil chemotaxis, and phagocytosis, thus improving viral binding affinity and entry and decreasing virus clearance. In addition, it has significant effects on the proteins by inducing glycosylation and altering the composition of complements, and glycosylation renders cells susceptible to viral inflammation and damage. The treatment of COVID-19 in patients with diabetes requires an integrated team approach to minimize the risk of medical complications and mortality. Moreover, physicians should adopt proactive strategies to care for persons with comorbidities. This strategy would help reduce the frequency of complications and mortality among patients and load on the healthcare system.Gazzaz Zohair JamilDe Gruyterarticlediabetes mellituscovid-19ace2cytokine stormcvdBiology (General)QH301-705.5ENOpen Life Sciences, Vol 16, Iss 1, Pp 297-302 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	diabetes mellitus covid-19 ace2 cytokine storm cvd Biology (General) QH301-705.5
spellingShingle	diabetes mellitus covid-19 ace2 cytokine storm cvd Biology (General) QH301-705.5 Gazzaz Zohair Jamil Diabetes and COVID-19
description	Several factors are linked with a higher risk of mortality from Coronavirus disease-19 (COVID-19), including male gender, increased age, hypertension, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, and cancer. Hyperglycemic COVID-19 patients have severe clinical problems, increased ICU admittance, machine-driven ventilation, and a substantial rise in inflammatory markers. Among all patients, those with diabetes or hyperglycemia have a two- to four-fold increase in mortality and severity of COVID-19 than those without diabetes. The primary cause of mortality in COVID-19 patients with diabetes is compromised immune response to viral infections. Increased blood sugar level probably affects intracellular degradation of bacteria, neutrophil chemotaxis, and phagocytosis, thus improving viral binding affinity and entry and decreasing virus clearance. In addition, it has significant effects on the proteins by inducing glycosylation and altering the composition of complements, and glycosylation renders cells susceptible to viral inflammation and damage. The treatment of COVID-19 in patients with diabetes requires an integrated team approach to minimize the risk of medical complications and mortality. Moreover, physicians should adopt proactive strategies to care for persons with comorbidities. This strategy would help reduce the frequency of complications and mortality among patients and load on the healthcare system.
format	article
author	Gazzaz Zohair Jamil
author_facet	Gazzaz Zohair Jamil
author_sort	Gazzaz Zohair Jamil
title	Diabetes and COVID-19
title_short	Diabetes and COVID-19
title_full	Diabetes and COVID-19
title_fullStr	Diabetes and COVID-19
title_full_unstemmed	Diabetes and COVID-19
title_sort	diabetes and covid-19
publisher	De Gruyter
publishDate	2021
url	https://doaj.org/article/a2e578d5f8454730bff6e533b8358c46
work_keys_str_mv	AT gazzazzohairjamil diabetesandcovid19
_version_	1718371856635920384

Diabetes and COVID-19

Ejemplares similares